- Home
- BCRX vs NAVI Comparison
BCRX vs NAVI Comparison
Compare BCRX & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- NAVI
- Stock Information
- Founded
- BCRX 1986
- NAVI 1973
- Country
- BCRX United States
- NAVI United States
- Employees
- BCRX N/A
- NAVI N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- NAVI Investment Bankers/Brokers/Service
- Sector
- BCRX Health Care
- NAVI Finance
- Exchange
- BCRX Nasdaq
- NAVI Nasdaq
- Market Cap
- BCRX 1.9B
- NAVI 1.5B
- IPO Year
- BCRX 1994
- NAVI N/A
- Fundamental
- Price
- BCRX $8.66
- NAVI $14.12
- Analyst Decision
- BCRX Strong Buy
- NAVI Hold
- Analyst Count
- BCRX 10
- NAVI 7
- Target Price
- BCRX $16.70
- NAVI $14.43
- AVG Volume (30 Days)
- BCRX 3.2M
- NAVI 964.6K
- Earning Date
- BCRX 08-04-2025
- NAVI 07-28-2025
- Dividend Yield
- BCRX N/A
- NAVI 4.53%
- EPS Growth
- BCRX N/A
- NAVI N/A
- EPS
- BCRX N/A
- NAVI 0.52
- Revenue
- BCRX $503,485,000.00
- NAVI $699,000,000.00
- Revenue This Year
- BCRX $38.50
- NAVI N/A
- Revenue Next Year
- BCRX $10.04
- NAVI $0.56
- P/E Ratio
- BCRX N/A
- NAVI $27.27
- Revenue Growth
- BCRX 41.67
- NAVI N/A
- 52 Week Low
- BCRX $6.02
- NAVI $10.53
- 52 Week High
- BCRX $11.31
- NAVI $16.97
- Technical
- Relative Strength Index (RSI)
- BCRX 35.06
- NAVI 45.79
- Support Level
- BCRX $8.40
- NAVI $13.84
- Resistance Level
- BCRX $8.79
- NAVI $14.94
- Average True Range (ATR)
- BCRX 0.25
- NAVI 0.52
- MACD
- BCRX -0.00
- NAVI -0.16
- Stochastic Oscillator
- BCRX 18.07
- NAVI 10.99
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.